Table 1.

Clinicopathological characteristics of the MTC patients enrolled.

	Parameter	Results
Primary cancer size, median, IQR (mm)		13, 8–24
T	1	35/63 (55.6%)
	2	11/63 (17.5%)
	3	16/63 (25.4%)
	4	1/63 (1.6%)
Lymph node involvement	N0	44/65 (67.7%)
	N1a	7/65 (10.8%)
	N1b	14/65 (21.5%)
Tumor stage	I	31/65 (47.7%)
	II	13/65 (20.0%)
	III	7/65 (10.8%)
	IV	14/65 (21.5%)
RET germline mutation	Present	17/69 (24.6%)
	Absent	52/69 (75.4%)
RET somatic mutation	Present	19/47 (40.4%)
	Absent	28/47 (59.6%)
RAS somatic mutation	Present	4/42 (9.5%)
	Absent	38/42 (90.5%)
Biochemical cure	Yes	42/60 (70.0%)
	No	18/60 (30.0%)